|
Craig Taylor, a member of the OptiMedica Board of Directors, has been an active venture capitalist since 1977. Specializing in the heathcare industry, he has served as a director for a number of publicly traded companies, including Adeza Biomedical, Pharmacyclics, and Solexa. He also serves as a director for several privately held companies, including ForteBio, Galileo Pharmaceuticals, K2 Optronics, Labcyte, and Zyomyx.
Mr. Taylor was a member of the Board of Directors of the National Venture Capital Association. He currently serves on the Board of Advisors of the MIT/Stanford Venture Laboratory. Before becoming a venture capitalist, he worked in the Office of Technology Licensing at Stanford University. He earned a B.Sc. and an M.S. in physics from Brown University, and an M.B.A. from Stanford University. | 